ZYBERNO
Stock Report
Updated Aug 30, 2026

VANDA PHARMACEUTICALS INC. (VNDA)

Healthcare • NASDAQ

$5.29

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
27.0/100
POOR BUSINESS
VANDA PHARMACEUTICALS INC. (VNDA) scores 27/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-85.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.15x)
Operating Margin (Operational Efficiency):CRITICAL (-86.1%)
Return on Capital (Capital Efficiency):CRITICAL (-55.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VANDA PHARMACEUTICALS INC. (VNDA) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VNDA generated -$127.30M in Owner Earnings. Capital was deployed as follows: $783.00K invested in capital expenditures. Reinvestment rate: 4.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.29
Market Cap:$318.60M

Valuation Multiples (3)

P/B Ratio:1.45x
P/S Ratio:1.48x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$347.74M

Price Action & Momentum (3)

Momentum Percentile:71 / 100
% of 52-Week High:53.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-56.8%
Reinvestment Rate:4.3%
Fundamental Growth Rate (g):-2.4%

Margin Analysis (3)

Operating Margin Ttm:-86.1%
Net Margin Ttm:-127.4%
Ebitda Margin:-79.6%

TTM Performance (2)

Operating Margin Ttm:-86.1%
Net Margin Ttm:-127.4%

Yield Metrics (2)

Earnings Yield:-$89.40
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-41.7%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-1.7%

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):6.5%
Operating Cash Flow Growth Rate (Linear):4.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.61x
Quick Ratio:1.60x
Cash Ratio:0.34x

Leverage Analysis (3)

Debt To Equity Ttm:0.15x
Debt-to-Equity Ratio:0.15x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:100,458,000.00
Cash And Cash Equivalents:55,882,000.00
Long Term Debt:$15.03M
Net Debt:$29.14M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $215.72M
Linear Growth: -1.7%
📊 Click to view full VNDA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$185.67M

Bottom Line Performance (3)

Net income TTM: -$274.85M
Linear Growth: -50.0%
📊 Click to view full VNDA Net Income analysis & methodology →
Income Before Tax:-$177.20M
Ebitda Ttm:-171,792,000.00

Operating Expenses (5)

Operating Expenses:401,391,000.00
R And D Expense:116,957,000.00
Sga Expense:263,450,000.00
Income Tax Expense:$97.65M
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:231.5%
Sga To Revenue Percentage:521.4%
Ebitda Margin:-79.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$412.47M
Current Assets:$264.48M
Ppe Net:2,578,000.00
Goodwill:0.00
Intangible Assets:$113.12M

Liability Structure (4)

Total Liabilities:192,282,000.00
Current Liabilities:164,026,000.00
Long Term Debt:$15.03M
Short Term Debt:$69.99M

Equity & Capital (3)

Equity:$220.19M
Retained Earnings:-$505.85M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:59,692,000.00
Inventory:1,678,000.00
Accounts Payable:69,994,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:2,107,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$126.51M
Linear Growth: 4.7%
Free cash flow TTM: -$127.30M
Linear Growth: 6.5%
📊 Click to view full VNDA Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:$20.23M
Capital Expenditures Ttm:783,000.00

Financing Activities (3)

Financing Cash Flow:-$776.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:13,878,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.64
Eps diluted TTM: -$4.64
Linear Growth: -47.9%
📊 Click to view full VNDA EPS analysis & methodology →
Earnings Per Share Ttm:-$4.56

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.58
Operating Cash Flow Per Share:-$1.82

Book Value & Capital (2)

Book Value Per Share:$3.66
Cash Per Share:0.93

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.45x
Working Capital Turnover Ttm:2.15x

Receivables Management (2)

Receivables Turnover Ttm:3.61x
Days Sales Outstanding Ttm:101.00

Inventory Management (2)

Inventory Turnover Ttm:128.56x
Days Inventory Outstanding Ttm:2.84

Payables & Cash Cycle (2)

Days Payable Outstanding:118.43
Cash Conversion Cycle:-14.59
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$127.30M

Damodaran Growth Analysis (2)

Reinvestment Rate:4.3%
Fundamental Growth Rate (g):-2.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):-1.7%
Net Income Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):6.5%
Operating Cash Flow Growth Rate (Linear):4.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-12.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:VNDA
Company Name:VANDA PHARMACEUTICALS INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:60.23M
Shares Outstanding Basic:60.23M
Shares Outstanding Diluted:60.23M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 20:37:00 UTC
Data Timestamp:2026-08-17T22:22:13.680575
Scroll to Top